<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2236">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05132049</url>
  </required_header>
  <id_info>
    <org_study_id>DA5211_BE_I</org_study_id>
    <nct_id>NCT05132049</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety Profiles After Administration of DA-5211 and Co-administration of DA-5211-R1 and DA-5211-R2 in Healthy Adult Volunteers</brief_title>
  <official_title>An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Phase 1 Study to Evaluate the Pharmacokinetic Characteristics and the Safety After Administration of DA-5211 and Co-administration of DA-5211-R1 and DA-5211-R2 in Healthy Adult Volunteer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetics and safety Profiles after administration of DA-5211 and co-administration of&#xD;
      DA-5211-R1 and DA-5211-R2 in healthy adult volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 13, 2021</start_date>
  <completion_date type="Anticipated">February 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 29, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt</measure>
    <time_frame>pre-dose~72 hours post-dose</time_frame>
    <description>area under the curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>pre-dose~72 hours post-dose</time_frame>
    <description>maximum plasma concentration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-5211</intervention_name>
    <description>single dose administration (DA-5211 one tablet once a day)</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-5211-R1 + DA-5211-R2</intervention_name>
    <description>single dose administration (DA-5211-R1 one tablet once a day + DA-5211-R2 one tablet once a day)</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers&#xD;
&#xD;
          -  BMI between 18 and 30 kg/m2&#xD;
&#xD;
          -  Body weight: Male≥50kg, Female≥45kg&#xD;
&#xD;
          -  Subjects who have signed an informed consent themselves after receiving detailed&#xD;
             explanation about clinical study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with allergy or drug hypersensitivity&#xD;
&#xD;
          -  Subjects with clinically significant medical history&#xD;
&#xD;
          -  Subjects with history of drug abuse or addicted&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>JiHyun Sung</last_name>
    <phone>+82-2-920-8369</phone>
    <email>jhsung@donga.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bumin Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>07590</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>TaeGon Hong, Ph.D</last_name>
      <email>tghong@bumin.co.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

